Effect of Urinary Protein C Inhibitor on Lipopolysaccharide-induced Disseminated Intravascular Coagulation in Rats

Mitsugu Fujita; Wakako Izutani; Yoshikazu Komurasaki

doi:10.1055/s-0037-1613967

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2000; 84(01): 54-58
DOI: 10.1055/s-0037-1613967

Commentary

Schattauer GmbH

Effect of Urinary Protein C Inhibitor on Lipopolysaccharide-induced Disseminated Intravascular Coagulation in Rats

Mitsugu Fujita

¹From the Development and Research Laboratories, JCR Pharmaceuticals Co., Ltd., Kobe, Japan

,

Wakako Izutani

¹From the Development and Research Laboratories, JCR Pharmaceuticals Co., Ltd., Kobe, Japan

,

Yoshikazu Komurasaki

¹From the Development and Research Laboratories, JCR Pharmaceuticals Co., Ltd., Kobe, Japan

› Institutsangaben

Abstract

Summary

The effect of urinary protein C inhibitor (uPCI) on disseminated intravascular coagulation (DIC) was investigated using an experimental DIC in rats. uPCI (0.5 and 1.0 mg/kg) was continuously administrated into the left femoral vein of the rats with lipopolysaccharide (50 mg/kg)-induced DIC. In all doses, uPCI significantly prevented the drastic changes in the parameters such as fibrinogen concentration, activated partial thromboplastin time (APTT), prothrombin time (PT), fibrin/fibrinogen degradation products (FDP) level, aspartate aminotransferase (AST) level and alanine aminotransferase (ALT) level. Furthermore, uPCI significantly inhibited the increase in the levels of plasma kallikrein and thrombin which act not only as the procoagulant proteases but also as the chemotactic factors to neutrophils and monocytes. These results show that uPCI may prevent hypercoagulation, the induction of secondary fibrinolysis and organ failure in the DIC model. Therefore, uPCI may be a useful agent for the clinical treatment of DIC.

Keywords

Urinary protein C inhibitor - DIC - experimental DIC in rat

Volltext

Referenzen

References
1 Espana F, Berrettini M, Griffin JH. Purification and characterization of plasma protein C inhibitor. Thromb Res 1989; 55: 369-84.
2 Suzuki K, Deyashiki Y, Nishioka J, Toma K. Protein C inhibitor: structure and function. Thromb Haemost 1989; 61: 337-42.
3 Stump DC, Thienpont M, Collen D. Purification and characterization of a novel inhibitor of urokinase from human urine. Quantitation and preliminary characterization in plasma. J Biol Chem 1986; 261: 12759-66.
4 Heeb MJ, Espana F, Geiger M, Collen D, Stump DC, Griffin JH. Immunological identity of heparin-dependent plasma and urinary protein C inhibitor and plasminogen activator inhibitor-3. J Biol Chem 1987; 262: 15813-6.
5 Espana F, Gilabert J, Estelles A, Romeu A, Aznar J, Cabo A. Functionally active protein C inhibitor/plasminogen activator inhibitor-3 (PCI/PAI-3) is secreted in seminal vesicles, occurs at high concentrations in human seminal plasma and complexes with prostate-specific antigen. Thromb Res 1991; 64: 309-20.
6 Laurell M, Christensson A, Abrahamsson PA, Stenflo J, Lilja H. Protein C inhibitor in human body fluids. Seminal plasma is rich in inhibitor antigen deriving from cells throughout the male reproductive system. J Clin Invest 1992; 89: 1094-101.
7 Rezaie AR, Cooper ST, Church FC, Esmon CT. Protein C inhibitor is a potent inhibitor of the thrombin-thrombomodulin complex. J Biol Chem 1995; 270: 25336-9.
8 Suzuki K, Nishioka J, Kusumoto H, Hashimoto S. Mechanism of inhibition of activated protein C by protein C inhibitor. J Biochem 1984; 95: 187-95.
9 Suzuki K, Nishioka J, Hashimoto S. Protein C inhibitor. Purification from human plasma and characterization. J Biol Chem 1983; 258: 163-8.
10 Meijers JCM, Vlooswijk RAA, Kanters DHAJ, Hessing M, Bouma BN. Identification of monoclonal antibodies that inhibit the function of protein C inhibitor. Evidence for heparin-independent inhibition of activated protein C in plasma. Blood 1988; 72: 1401-3.
11 Meijers JCM, Kanters DHAJ, Vlooswijk RAA, van Erp HE, Hessing M, Bouma BN. Inactivation of human plasma kallikrein and factor XIa by protein C inhibitor. Biochemistry 1988; 27: 4231-7.
12 Pratt CW, Macik BG, Church FC. Protein C inhibitor: purification and proteinase reactivity. Thromb Res 1989; 53: 595-602.
13 Vicente V, Espana F, Tabernero D, Estelles A, Aznar J, Hendl S, Griffin JH. Evidence of activation of the protein C pathway during acute vascular damage induced by Mediterranean spotted fever. Blood 1991; 78: 416-22.
14 Cooper ST, Whinna HC, Jackson TP, Boyd JM, Church FC. Intermolecular interactions between protein C inhibitor and coagulation proteases. Biochemistry 1995; 34: 12991-7.
15 Huber R, Carrell RW. Implications of the three-dimensional structure of a₁-antitrypsin for structure and function of serpins. Biochemistry 1989; 28: 8951-66.
16 Suzuki K, Deyashiki Y, Nishioka J, Kurachi K, Akira M, Yamamoto S, Hashimoto S. Characterization of a cDNA for human protein C inhibitor. A new member of the plasma serine protease inhibitor superfamily. J Biol Chem 1987; 262: 611-6.
17 Carrell R, Travis J. a₁-Antitrypsin and the serpins: variation and countervariation. Trends Biochem Sci 1985; 10: 20-4.
18 Moore KL, Andreoli SP, Esmon NL, Esmon CT, Bang NU. Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro. J Clin Invest 1987; 79: 124-30.
19 Kagawa H, Komiyama Y, Nakamura S, Miyake T, Miyazaki Y, Hamamoto K, Masuda M, Takahashi H, Nomura S, Fukuhara S. Expression of functional tissue factor on small vesicles of lipopolysaccharide-stimulated human vascular endothelial cells. Thromb Res 1998; 91: 297-304.
20 Suzuki K, Kusumoto H, Nishioka J, Komiyama Y. Bovine plasma protein C inhibitor with structural and functional homologous properties to human plasma protein C inhibitor. J Biochem 1990; 107: 381-8.
21 Pratt CW, Church FC. Heparin binding to protein C inhibitor. J Biol Chem 1992; 267: 8789-94.
22 Sheffield WP, Wu YI, Blajchman MA. Antithrombin: Structure and Function. In: Molecular Basis of Thrombosis and Hemostasis. High KA, Roberts HR. eds. New York: Marcel Dekker Inc; 1995: 355-77.
23 Rubin RN, Colman RW. Disseminated intravascular coagulation. Approach to treatment. Drugs 1992; 44: 963-71.
24 Lijnen HR, Van Hoef B, Collen D. Influence of cyanogen-bromide-digested fibrinogen on the kinetics of plasminogen activation by urokinase. Eur J Biochem 1984; 144: 541-4.
25 Wu HL, Chang BI, Wu DH, Chang LC, Gong CC, Lou KL, Shi GY. Interaction of plasminogen and fibrin in plasminogen activation. J Biol Chem 1990; 265: 19658-64.
26 Buller HR, Hobbelen PMJ, Princen AWN, Moelker HCT, ten Cate JW. The effects of antithrombin III, heparin and a novel heparinoid infusions on the bleeding tendency using an experimental model in the rat. Thromb Res 1983; 31: 787-97.
27 Schapira M, Despland E, Scott CF, Boxer LA, Colman RW. Purified human plasma kallikrein aggregates human blood neutrophils. J Clin Invest 1982; 69: 1199-202.
28 Jochum M, Machleidt W, Neuhof H, Fritz H. Proteinases. In: Pathophysiology of Shock, Sepsis, and Organ Failure. Schlag G, Redl H. eds. Berlin Heidelberg: Springer-Verlag; 1993: 46-60.
29 Katsuura Y, Okamoto S, Ohno N, Wanaka K. Effects of a highly selective synthetic inhibitor of plasma kallikrein on disseminated intravascular coagulation in rats. Thromb Res 1996; 82: 361-8.